Ivosidenib (AG-120) is an orally active, selective inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1). It effectively reduces levels of the oncometabolite D-2-hydroxyglutarate (2-HG) in vivo by blocking its aberrant production. Ivosidenib promotes cellular differentiation and inhibits proliferation in tumor cells harboring IDH1 mutations. With a favorable safety profile and demonstrated clinical activity, it holds therapeutic potential for the treatment of acute myeloid leukemia (AML) and other mIDH1-associated malignancies. Reagent grade, for research purpose.
Usually ships within 24 hours.